SUMMARY To determine the minimum effective dose of metronidazole in the treatment of vaginal trichomoniasis, a randomised clinical trial comparing single 1-g and 2-g doses was carried out on 163 patients attending sexually transmitted diseases and family planning clinics. Seventytwo of 86 (84q7o) patients receiving a single 2-g dose of metronidazole were cured compared with only 42 of 77 (5507) receiving a 1-g dose. The body weight of the patient was a significant variable affecting treatment outcome only in the latter group; 69% of patients weighing more than 57 kg or less were cured compared with only 43% of those weighing more. Patients who failed after either dose regimen were retreated with a single 2-g dose. Eighteen of 21 (86%7o) and seven of 10 (70%) failures with the initial 1-g and 2-g doses respectively were cured. A single 1-g dose of metronidazole is not recommended as routine treatment for vaginal trichomoniasis.
Introduction
A single 2-g dose of metronidazole is recognised as an effective treatment for trichomonal vaginitis and gives comparable results to the standard seven-day course of 250 mg three times daily. '-" The minimum single dose has not, however, been well established, although the efficacy of single l-g and 1* 5-g doses was reported by one investigator to be equivalent to a 2-g dose. 6 I The purpose of this study was to confirm the preceding results with a l-g dose in the hope of determining the lowest effective dose of metronidazole for routine use in trichomoniasis in order to minimise costs and any potential toxicity of the drug.
informed of the nature of the trial and follow-up procedures before entry into the study. The diagnosis of trichomoniasis was initially suspected clinically in patients who complained of increased or malodorous vaginal discharge and perineal pruritus or soreness. This was confirmed by speculum examination, demonstration of viable trichomonads in a wet-mount preparation, and subsequent culture of the organism from vaginal secretions in modified Diamond's medium. After entry into the study, the patient's body weight and symptoms were recorded and she was randomly assigned to receive either a single l-g or 2-g dose of metronidazole by a series ofrandom numbers prepared by the pharamacy. 
Discussion
In a randomised prospective clinical study a single 2-g dose of metronidazole was shown to be significantly more effective than a 1-g dose. The treatment outcome in this study following the 2-g dose was similar to that reported previously in which cure rates ranged from approximately 80070 to 957o.'14 [7] [8] [9] [10] [11] The latter figure occurred in a clinic population where reinfection as a cause of treatment failure was recognised and apparently eliminated.8 The proportion of treatment failures that were actually due to reinfection in our study, despite treatment of the principal male consorts and explicit instructions to the patients to avoid sexual intercourse, is unknown.
In the l-g dosage group, the cure rate of only 55%7o is in clear contrast to the previously reported 100%o cure rate.6 7 The reason for this difference is not known but could be partly attributed to reinfection. As a result of randomisation, however, reinfection as a cause of treatment failure would be similar in both dosage groups and therefore should be no greater than 16%o (the total failure rate after the 2-g dose). The conclusion from our study is that the single l-g dose of metronidazole is significantly inferior to the 2-g dose and is not indicated for the routine treatment of symptomatic or clinically evident trichomoniasis.
Interestingly, the body weight of the patient was a significant variable affecting treatment outcome in the l-g dosage group. To our knowledge, response to metronidazole treatment has not been correlated before with the patient's weight. In patients weighing 57 kg or less, 6907o responded to the single I -g dose but it was still inferior to the overall cure rate of 84%o after a 2-g dose. Therefore, even in patients weighing less than 57 kg, a single l-g dose could not be recommended routinely.
Optimal treatment after failure with a single 2-g dose is not well established. In our study, 7007o of patients responded to a second 2-g dose which suggests that this is a reasonable therapeutic approach. Treatment failures after a second 2-g dose when reinfection is not a consideration should be investigated, however, for the possibility of a metronidazole-resistant strain of Trichomonas vaginalis, [12] [13] [14] 
